"Pharmaceutical Speed Reader" Kangji Medical Hkex listed Kangsino recombined the new crown vaccine approved.

Fujian medical supplies with a volume of procurement enterprises announced; Shaanxi Province Drug Administration to implement a blacklist system; Taibang biological claims to Xinjiang Deyuan more than 460 million yuan; Soyuan biological completion of nearly 600 million yuan C round of financing; Shi Taili / Hengrui "iodine sea alcohol injection" approvedFujian Provincial Medical Insurance Bureau issued "on the publication of Fujian Province medical supplies centralized band procurement documents notice", notice published in line with the quotation conditions of the list of enterprises, and announced artificial joints, retention needles, ultrasonic knives, analgesic pumps, these four types of medical supplies concentrated band procurement(Fujian Provincial Medical Insurance Bureau)Shaanxi Provincial Drug Administration issued "on the public solicitation of "Shanxi Province Drug Safety" blacklist " information sharing and joint disciplinary measures (trial)" notice, intended to strengthen drug (including medical devices) safety supervision, strengthen the implementation of corporate responsibility, promote the construction of the integrity system, improve the industry ban and exit mechanism(The Shaanxi Provincial Drug Administration)28, Shandong Medical Insurance Bureau issued a notice on the transfer of some drugs out of the "Shandong Province basic medical insurance injury insurance and maternity insurance drugs directory (2017 edition)""Notice" pointed out that from July 1, 2020, the first batch of state key monitoring of the scope of the catalog of rational drugs, the nine drugs will be unified out of the provincial drug catalogue, no longer included in the scope of fund paymentA separate three-year programme of work for the digestion of additional varieties in the remaining provinces has been developed separately(Shandong Provincial Health Insurance Bureau)the official website of the Liaoning Provincial Health and Health Commission published the "Liaoning Province medical and health industry reporting incentives for violations of laws and regulations (draft for comments), the Measures clearly defined the scope of the medical and health industry violations of the reporting incentives, reporting reward standards, supervision and management and other 25 rules(Liaoning Health and Health Commission)29, Soyuan Bio announced the completion of the RMB 590 million scale of C round financingThis round of financing is led by CICC Qide Innovative Biopharmaceutical Equity Investment Fund, with the participation of existing shareholders Kuyou Capital, Share Investment, CITIC Securities Investment and Xianxian Capital, and new shareholders such as PCCW Capital, China Central Capital and China Investment Hanrun Investment(Pharmaceutical Ming Kangd)29, Kangji Medical officially listed on the Hong Kong Stock Exchange, the securities code is "09997.HK." The offering was priced at HK$13.88 per share and opened at HK$25.9 per share, up 86.6 per cent from the offering price, totalling 225 million shares(Shell)Cornerstone Pharmaceuticals announced a strategic partnership with Stone Research Accompanying Diagnostics (CDx), which will jointly develop and commercialize the CDx reagent in China, the research drug pralsetinib developed by Keystone Pharmaceuticals partner Blueprint Medicines, to detect RET gene mutations in tumor patients On the 28th of , Novartis's clinical application for Inclisiran injection was accepted by CDE The drug is Novartis's $9.7 billion acquisition of The Medicines Company for a first-of-its-kind small-molecule interfering RNA (siRNA) cholesterol-lowering drug, which requires only twice a year Novartis has filed an Inclisiran listing application with the FDA and EMA (Pharma Rubik's Cube) Green Leaf Pharmaceuticals Group is entering a clinical phase in China with Lurbinectedin, an anti-tumor innovation licensed by Spanish biopharmaceutical company Pharma Mar, S.A At present, the clinical trial application of the drug has been accepted by the Drug Review Center of the State Drug Administration for the treatment of small cell lung cancer (Sina Pharmaceutical News) NMPA's latest announcement, Baiji Shenzhou's New PD-1 Antibody Drug for reliever-Zhumonotininjection submitted a new indication (sNDA) application, and received acceptance This is the fifth listing application submitted in China for reliion bead sing-ins (Pharmaceutical Mingkang) CDE official website shows that Dongsun Pharmaceutical s3 generic drug "oseltamivir dry suspension agent phosphate" listing application by the drug review center, become the third domestic production of this dosage form of enterprises (Insight Database) 28, CDE official website shows that Jiangsu Wanbang submitted the "recombinant Lai Lu insulin injection" listing application by the drug trial center Recombinant insulin is a new type of insulin analogue, which acts quickly, has a shorter duration of action, and is more in line with the insulin secretion curve during physiological meals (Insight Database) Oseicon Pharmaceuticals submitted a listing application for a generic version of apoepatablet, classified as 4, and was accepted on June 29 Aiqupopa ethanolamine tablets are a non-peptide oral platelet receptor agonisant, which is currently available only to Novartis's Rifland (Pharmaceutical Mingkang) 28, Jiangxi Dongfu Pharmaceutical to copy 3 categories of inhalation of the new solution of bromate hydrochloric acid has been accepted by CDE, acceptance number CYHS2000418 In 2019, china's public medical institutions terminal bromine hydrochloric acid new sales of 2.304 billion yuan, there is currently no inhalation agent form on the market sales (Minnet.com) Division Taili issued a notice that its new four types of generic iodized sea alcohol injection has been approved by the State Drug Administration for listing, as is the same as through the consistency evaluation HengRui reached a cooperation agreement with Taliafa on May 12, and Hengrui will be responsible for the commercial operation of iodized sea alcohol injections and iodypaol injections (Pharma Rubik's Cube) 28, Sansheng Pharmaceuticals announced that its Sansheng Health Pharmaceuticals developed anti-white interlein 4 receptor alpha (IL-4Ra) humanized monoclonal antibody drug recently obtained the FDA clinical trial approval for the treatment of ad hoc dermatitis (eczema) patients The company will launch a clinical trial of the product in the United States as soon as possible In addition, the product in the domestic clinical trial application was recently received by NMPA Ascendis Pharma, a Danish biopharmaceutical company , recently announced that it has filed a weekly application with the FDA for a weekly license for the long-acting growth hormone TransCon hGH, a human growth hormone,a long-acting pre-life drug administered once a week to treat growth hormone deficiency in children (Biovalley) Roche recently announced the launch of the European Union CE-IVD-certified automated digital pathology algorithm - uPath PD-L1, for non-small cell lung cancer image analysis The algorithm provides pathologists with an automated evaluation of scanned objective and repeatable slide images, potentially assisting diagnosis, and ultimately providing patients with targeted treatment options (BioValley) Novartis recently announced that the European Medicines Agency's Human Products Committee has issued an active review, recommending approval of the anti-inflammatory drug Xolair, as an additional therapy for the nasal corticosteroids, for the use of INC can not adequately control the condition of severe chronic nasal-sinary sinusitis with nasal polyps adult patients (-18 years) (Biovalley) the first three recently announced that the European Medicines Agency's General Pharmaceutical Products Commission for pexidartinib's listing application issued a negative opinion The MAA applied for approval for the treatment of pexidartinib for treatment in adult patients with symptomatic tendon cytoma, which has severe morbidity or functional limitations and is not suitable for surgical improvement (Biovalley) Vertex announced that the European Medicines Agency's Human Products Committee has issued a positive review of the recommendation to approve Kaftrio and Kalydeco 150mg combination drug treatment for patients with cystic fibrosis aged 12 years, specifically: cystic fibrosis transmembrane conductivity regulator gene in the presence of a F508 mutation and a minimum functional mutation (F/MF) patients, or patients with 2 F508 (Fdel) (Bio Valley)